The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy
Open accessAbstract
Our intent is to examine the predictive role of Charlson comorbidity index (CCI) on mortality of patients with type 2 diabetic nephropathy (DN). Based on the CCI score, the severity of comorbidity was categorized into three grades: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores ≥5. Factors influencing mortality and differences between groups stratified by CCI were determined by logistical regression analysis and one-way analysis of variance (ANOVA). The impact of CCI on mortality was assessed by the Kaplan-Meier analysis. A total of 533 patients with type 2 DN were enrolled in this study, all of them had comorbidity (CCI score >1), and 44.7% (238/533) died. The mortality increased with CCI scores: 21.0% (50/238) patients with CCI scores of 1-2, 56.7% (135/238) patients with CCI scores of 3-4, and 22.3% (53/238) patients with CCI scores ≥5. Logistical regression analysis showed that CCI scores, hemoglobin, and serum albumin were the potential predictors of mortality (P<0.05). One-way ANOVA analysis showed that DN patients with higher CCI scores had lower levels of hemoglobulin, higher levels of serum creatinine, and higher mortality rates than those with lower CCI scores. The Kaplan-Meier curves showed that survival time decreased when the CCI scores and mortality rates went up. In conclusion, CCI provides a simple, readily applicable, and valid method for classifying comorbidities and predicting the mortality of type 2 DN. An increased awareness of the potential comorbidities in type 2 DN patients may provide insights into this complicated disease and improve the outcomes by identifying and treating patients earlier and more effectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
How to measure comorbiditya critical review of available methods
DEGROOT, V, BECKERMAN, H., LANKHORST, G., & BOUTER, L. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00585-1 · Cited by 1,757
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544 · cited 2×
“…is the co-occurrence of multiple diseases in one person (Guralnik, 1996). van den Akker et al. (1998) made a useful distinction between multi-morbidities (i.e., the co-occurrence of multiple chronic or acute diseases and medical conditions in one person) and comorbidity (Feinstein, 1970).”
BackgroundMethodvan den Akker, M., Buntinx, F., Metsemakers, J. F. M., Roos, S., & Knottnerus, J. A. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00306-5 · Cited by 1,027
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions
Ritz, E., Rychlík, I., Locatelli, F., & Halimi, S. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70035-1 · Cited by 806
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75728 · Cited by 416
Unrecognized Anemia in Patients With Diabetes
Thomas, M. C., MacIsaac, R. J., Tsalamandris, C., Power, D., & Jerums, G. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1164 · Cited by 347
Cited by
Pipek, L. Z., Baptista, C. G., Nascimento, R. F. V., Taba, J. V., Suzuki, M. O., do Nascimento, F. S., Martines, D. R., Nii, F., Iuamoto, L. R., Carneiro-D’Albuquerque, L. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237740 · Cited by 71
The relationship between obesity and other medical comorbidities
Afolabi, H. A., Zakariya, Z. B., Ahmed Shokri, A. B., Mohammad Hasim, M. N. B., Vinayak, R., Afolabi-Owolabi, O. T., & Elesho, R. F. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2019.100164 · Cited by 54
Predicting bloodstream infection outcome using machine learning
Zoabi, Y., Kehat, O., Lahav, D., Weiss-Meilik, A., Adler, A., & Shomron, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-99105-2 · Cited by 37
Shaka, H., Wani, F., El-Amir, Z., Dahiya, D. S., Singh, J., Edigin, E., Eseaton, P., & Kichloo, A. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001901 · Cited by 21
Hood, R. C., Borra, S., Fan, L., Pollom, R. D., Huang, A., & Chen, J. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.006 · Cited by 9
Metadata
- Authors
- Huang, Y.-Q., Gou, R., Diao, Y.-S., Yin, Q.-H., Fan, W.-X., Liang, Y.-P., Chen, Y., Wu, M., Zang, L., Li, L., Zang, J., Cheng, L., Fu, P., & Liu, F.
- Venue
- Journal of Zhejiang University SCIENCE B
- Publisher
- Zhejiang University Press
- Published
- 2014-01
- Volume
- 15
- Issue
- 1
- Pages
- 58-66
- ISSN
- 1673-1581 (ISSN-L)
- 1862-1783
- OpenAlex
- W2081034937
- Cited by
- 298
- References
- 26
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. https://app.cochat.ai/papers/10.1631/jzus.b1300109
- The paper
- Huang, Y.-Q., Gou, R., Diao, Y.-S., Yin, Q.-H., Fan, W.-X., Liang, Y.-P., Chen, Y., Wu, M., Zang, L., Li, L., Zang, J., Cheng, L., Fu, P., & Liu, F. (2014). Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. Journal of Zhejiang University SCIENCE B. https://doi.org/10.1631/jzus.b1300109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.